All patients receiving autografts for acute leukaemia in remission between 1 January 1981 and 31 December 1996 and reported to the European Group for Blood and Marrow Transplantation and had a relapse, were included. The patients underwent an allograft (n = 90, group A), were treated with chemotherapy (n = 2584, group B) or received a second autograft (n = 74, group C). The 2-year survival after relapse was 32 ؎ 5%, 11 ؎ 1% and 42 ؎ 6% in groups A, B and C, respectively. In group A, those with an HLA-A, -B and -DR compatible related or unrelated donor had a 2-year survival of 37 ؎ 7% compared to 13 ؎ 8% for those receiving a graft from an HLA mismatched donor (n = 20). The following factors were associated with better survival in multivariate analyses: an interval from first autograft to relapse Ͼ5 months (P Ͻ 0.00001), a first autograft performed later than 1991 (P Ͻ 0.00001), patient age below 26 years (median, P Ͻ 0.002), group B vs HLA mismatches from group A (P = 0.002), group C vs group B (P Ͻ 0.005), patients who were not treated with total body irradiation at first autograft (P Ͻ 0.02) and patients in first remission at first autograft (P = 0.02). To conclude, the poor outcome in these patients was improved if a second autograft was feasible (P Ͻ 0.005), or if an HLA-matched allograft was performed (NS). Bone Marrow Transplantation (2000) 25, 1053-1058.
related mortality (TRM), compared to allogeneic bone marrow transplantation (BMT), because of the absence of graftversus-host disease (GVHD). [6] [7] [8] [9] [10] Due to the lack of GVHD, there is no graft-versus-leukaemia effect. [11] [12] [13] [14] ABMT also carries a risk of reinjecting residual leukaemic cells. 15 Therefore, ABMT is associated with a higher risk of relapse, compared to BMT. [6] [7] [8] [9] [10] A major threat to patients undergoing ABMT is therefore recurrent disease. In patients who have a relapse after ABMT, the outcome is poor, but there are limited data reported. The three treatment possibilities for these patients include a search for a suitable donor to perform an allotransplantation, chemotherapy or palliative therapy and to perform a second ABMT. We here summarise the experience within the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) with these three treatment modalities.
Patients and methods

Patients
All patients who underwent ABMT in complete remission (CR) for acute leukaemia between 1 January 1981 and 31 December 1996, were reported to the Acute Leukaemia Working Party of the EBMT and had a relapse were included in the study. Follow-up time from first ABMT was a median of 17 (range 1-148) months and from relapse 6 months. Patient characteristics in the three groups, those who underwent an allograft (group A), those treated with chemotherapy (group B) and those receiving a second autograft (group C), are summarised in Table 1 . There were fewer patients with ALL in group C, compared to the other two groups. The first autograft was performed more recently in group A, compared to groups B and C. Conditioning at first autograft more often contained total body irradiation (TBI) in groups A and B, compared to group C. The source of stem cells given to the patients, bone marrow, peripheral blood progenitor cells (PBPC) or both, differed between the groups. Time from first autograft to relapse was shorter in group B, compared to the two other groups. a Patients in CR1. ALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia; CR = complete remission; TBI = total body irradiation; Bu = busulfan; Cy = cyclophosphamide; ABMT = autologous bone marrow transplantation; PBPC = peripheral blood progenitor cells. P values are in italics.
Time from relapse to second transplant was longer in group A vs group C (P = 0.0003).
Donors
Among the allogeneic donors, 62 were HLA-compatible donors which included 33 HLA-A, -B and -DR-compatible unrelated donors, 26 HLA-identical siblings, two HLAidentical parents and one syngeneic donor. HLA typing was serologic for class I and serologic or genomic for class II. Among 20 HLA-mismatched donors, 14 were family donors and six were mismatched unrelated donors. HLA data in the donor were missing in eight. Immunosuppression given to the allograft recipients consisted of cyclosporine combined with methotrexate in 37, T cell-depletion in 11, cyclosporine alone in nine and information was missing in 33.
Statistical methods
All analyses were performed with the SPSS statistical package. Curves for patient survival were calculated using the product limit method according to Kaplan and Meier. 16 Survival was calculated from the time of relapse after the first autograft and the endpoint was alive or dead at the time of last assessment. The significance of differences between the curves was estimated by the log-rank test (Mantel-Cox). Cox multivariate regression analysis was performed to estimate the various potential risk factors for survival. 17 All factors differing significantly between the three groups in univariate analyses and all prognostic factors by univariate analysis (P Ͻ 0.2) were included in the multivariate analysis. The second transplant was included in the Cox model as a time-dependent co-variate. Furthermore, in the multivariate analysis, the following factors were included: diagnosis, source of stem cells, HLA match vs mismatch, patient sex, year of transplantation, status at first autograft (CR1 vs CR2+), pretransplant regimen (TBI vs chemotherapy), age (26 years vs Ͼ26), interval from CR to first autograft and interval first autograft to relapse.
Results
Two years after relapse following first autograft the overall survival was 32 Ϯ 5% (Ϯ95% confidence interval) in group Survival in patients with acute leukaemia who relapsed after autograft and thereafter were treated with an allograft (n = 90), group A, with chemotherapy (n = 2585), group B or were treated with a second autograft (n = 74), group C. In the Kaplan-Meier curves, the delay between relapse and second transplant is not taken into account. The Cox model is more reliable (Table 4) .
A, 11 Ϯ 1% in group B and 42 Ϯ 6% in group C ( Figure  1 ). Five years after relapse, there were only 24 patients at risk and the survival probability in group B was only 5%. In group A, those receiving a graft from an HLAcompatible related or unrelated donor had a 2-year probability of survival of 37 Ϯ 7% vs 13 Ϯ 8% for those receiving HLA-mismatched marrow. In group C, in patients where stem cells were collected before first autograft, only 6/33 (18%) were in CR at second autograft, compared to 22/26 (85%), in patients who were reharvested before second autograft (P Ͻ 0.0001). Survival at 2 years after relapse following first autograft was 31 Ϯ 8% and 59 Ϯ 10% in the two groups, respectively (P = 0.03).
Recurrent leukaemia was the most common cause of death in all patients, especially in groups B and C (Table 2) . Other common causes of death were infections including interstitial pneumonitis and toxicity, especially in group A.
Factors associated with a better survival in univariate analysis included group A vs group B, group C vs group Bone Marrow Transplantation Table 3 Univariate analysis: risk-factors for survival in the global population (first ABMT). Two-year survival % ± 95% confidence interval in log rank Group A: allograft after relapse: n = 90. Group B: chemotherapy only after relapse: n = 2584. Group C: second autograft after relapse: n = 74. Abbreviations, see Table 1 .
2-year P value survival
B, younger age, CR1 vs CR2+, no TBI during conditioning before first autograft, long interval from CR to first autograft and, most of all, a longer interval from first autograft to relapse (Ͼ5 months) ( Table 3) . In multivariate analysis, the same factors were associated with a better survival, including group C over group B (Table 4 ). The only exception was that there was no difference between patients who received an allograft from an HLA-compatible donor and patients who received only chemotherapy, but an allograft from a mismatched donor was associated with a lower survival compared to chemotherapy. In addition, results were significantly improved for patients who received the first autograft after 1991.
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Discussion
As expected, patients who have a relapse after an autograft for acute leukaemia and are treated with chemotherapy have a very poor outcome and only 5% were alive at 5 years. A number of risk factors were identified in these patients. The most important was a long interval from first ABMT to relapse (Table 4) . Those with an early relapse have a highly resistant cell clone with a high probability of subsequent relapse. Recurrent leukaemia was also the commonest cause of death in all three groups (Table 2) . In group A, recurrent leukaemia was less common than in the other two groups. However, procedure-related complications such as infections and toxicity were common causes of death in the allograft recipients. This is not unexpected, because these are indeed high-risk patients.
Patients who had their first ABMT performed after 1991 had an improved survival after relapse. This is in contrast to the overall experience with primary ABMT where no improvement has been seen by years. 2 That patients who relapse have a better outcome in more recent years may be due to better management. This may include the use of granulocyte colony-stimulating factor (G-CSF), better infection control and maybe more effective chemotherapy. 1, 18, 19 Patients below the median 26 years of age had a better survival. Young patients tolerated conditioning better and this is also in accordance with previous studies in patients undergoing primary allografts. 20 It is obvious that age is important in this high-risk group of patients who have been treated with myeloablative therapy and ABMT and thereafter relapsed and received additional high-dose chemotherapy with or without a new graft. Patients treated with TBI at the first autograft had a poor outcome. This may be due to a selection of patients with a more or less therapy-resistant leukaemic cell clone. That patients who relapsed and underwent first ABMT in CR1 had a better outcome than those undergoing first ABMT in later Table 4 Significant prognostic factors by multivariate analysis: starting point, date of relapse, endpoint, alive or death
Results (survival after relapse) P value RR (95% CI)
Interval ABMT-relapse Ͻ0.00001 0. Number of patients included in multivariate analysis: n = 1876. Group A, HLA-matched allograft: n = 47; HLA-mismatched allograft: n = 14. Group B, chemotherapy: n = 1761. Group C, 2nd autograft: n = 54. Abbreviations, see Table 1 .
remission is in accordance with the experience in ABMT and allografts. 2, 20 One of the major concerns of the comparison between the chemotherapy and transplantation groups is that we do not know the percentage of patients for whom a transplantation would have been feasible in the chemotherapy group. Thus, we cannot conclude that a second transplant is a favourable factor in itself, because we do not have any information on the reasons for no second transplant. Is it due to the patient's status, the failure to find an HLAmatched donor, the non-availability of viable autologous stem cells, or the physician's choice? However, the second transplant was analysed as a time-dependent co-variate in the Cox model, which means that all patients are kept in the chemotherapy group until they received a graft. Patients who received a second autograft had a significantly better survival than those in group B when all significant riskfactors were competing in the multivariate analysis (Table  4) . From this study it is not possible to analyze if it is better to harvest the autologous stem cells for a second autograft before the first or the second autograft. The reason for this is the close correlation between reharvest and remission at second autograft (P Ͻ 0.0001). In patients who were in remission prior to second autograft, it was more likely that reharvesting was performed. However, in those who were not in remission, it was more likely that previously collected stem cells were used for retransplantation.
When analysed as a time-dependent co-variate in the model, taking into account the interval from relapse to graft, recipients of HLA-mismatched allografts had a worse outcome, compared to the chemotherapy group (Table 4) .
HLA typing in group A was serologic for many patients and in more recent years genomic, especially for class II. By genomic typing and matching, outcome has improved after transplantation with unrelated donors. 21, 22 However, in group A outcome was not different in those receiving grafts from HLA-identical siblings, compared to those receiving marrow from unrelated donors. 23 One-year leukaemia-free survival in the MUD group was 44%, compared to 40% in HLA-identical siblings. At 2 years, LFS was around 30% in both groups. The small numbers makes it meaningless to evaluate the role of genomic typing in these patients. Nonetheless, the recipients of mismatched marrow had a high transplant-related mortality being 75% 1 year after relapse of first ABMT, compared to 39% in recipients of HLA-A, -B and -DR-compatible unrelated marrow and 50% in HLA-identical siblings. 23 If recipients of HLA-mismatched marrow were excluded, survival in group A was not worse compared to groups B or C (Table  4) . It may be questioned if there is a role for a second allograft in patients who relapse after an ABMT for acute leukaemia. In a separate study comparing second autografts with HLA-matched allografts, the data suggested that an allograft may be considered if TBI was not used at the first ABMT. 23 Because the HLA-mismatched allografts did poorly, this may not be recommended at most transplant centres. However, some centres have excellent results performing HLA-mismatched transplants and may therefore favour an allograft even if an HLA-A, -B, -DR-compatible donor is not available. 24 In the decision of which procedure to choose, the experience at the single centre is of utmost importance.
To conclude from this study, the vast majority of patients who relapse after ABMT for acute leukaemia die from original disease. However, survival was significantly improved if a second ABMT was feasible. An HLA-matched allograft may also be an alternative with similar outcome as the autografts, although not significantly different from the chemotherapy group in the multivariate analysis.
